포스터 발표 : 포스터 연제 ; 장기간 Furosemide를 복용한 환자에서 동반된 신석회화증(Nephrocalcinosis) 1예

권창일 ( Kwon Chang Il ),권건호 ( Kwon Geon Ho ),김형태 ( Kim Hyeong Tae ),황경화 ( Hwang Gyeong Hwa ),권오선 ( Kwon O Seon ) 대한신장학회 1999 춘계학술대회 초록집 Vol.18 No.2

스테레오 비젼을 이용한 움직임 검출

권창일(Chang Il Kwon),원성혁(Sung Hyuk Won),김민기(Min Gi Kim),이기식(Gee Sik Lee),김광택(Kwang Taek Kim),정일준(In Jun Jeong) 대한전자공학회 2000 대한전자공학회 학술대회 Vol.2000 No.6

40세 여성에서 발생한 극세포해리 극세포종 1예

권창일 ( Chang Il Kwon ),정서미곤 ( Seo Mi Gon Jeong ),김지연 ( Chi Yeon Kim ) 대한피부과학회 2021 大韓皮膚科學會誌 Vol.59 No.7

Acantholytic acanthoma is a rare benign neoplasm of epidermal keratinocytes that clinically presents as a solitary, asymptomatic keratotic papule or nodule on the trunk. A 40-year-old female visited our hospital with a 20-year history of a single papule on her right thigh. On physical examination, the lesion measured 0.5×0.4 cm in size and appeared brown in color with central hyperkeratosis. Histopathological evaluation showed hyperkeratosis, acanthosis, papillomatosis, dyskeratosis, and acantholysis. Only six cases of acantholytic acanthoma have been reported in Korea. We report a rare case of acantholytic acanthoma that occurred in a 40-year-old female who presented with a keratotic papule on her right thigh. (Korean J Dermatol 2021;59(7):564∼567)

췌장암에 의해 발생한 위 정맥류 출현

권창일 ( Chang Il Kwon ),홍성표 ( Sung Pyo Hong ),박필원 ( Pil Won Park ) 대한소화기학회 2006 대한소화기학회지 Vol.48 No.4

여성 외음부에 발생한 경화 위축성 태선에 대한 임상 및 병리조직학적 고찰

권창일 ( Chang Il Kwon ),김동출 ( Dong Chul Kim ),김지연 ( Chi Yeon Kim ) 대한피부과학회 2020 大韓皮膚科學會誌 Vol.58 No.10

Background: Lichen sclerosus et atrophicus is an uncommon, benign, chronic lymphocyte-mediated inflammatory dermatosis that occurs mainly in the genital area. It causes substantial discomfort and morbidity, mostly in adult women. Objective: To investigate the clinicopathological characteristics of patients with vulvar lichen sclerosus et atrophicus. Methods: We retrospectively reviewed the clinical and histopathological features of 25 patients diagnosed with vulvar lichen sclerosus et atrophicus, who visited the dermatologic department between January 2009 and June 2017. Results: The average age was 54.2 years, and the disease duration was mostly less than 1 year. The major clinical features were diffuse patch, followed by diffuse plaque and multiple macules. It often presented with diabetes mellitus, thyroid disease, and hypertension. Itching was the most common symptom, followed by pain and burning sensations. Histopathological findings were hyperkeratosis with follicular plugging; atrophy and loss of rete ridge elongation in the epidermis; liquefaction degeneration and keratinocyte necrosis in the dermo-epidermal junction; collagen fibers hyalinization; and infiltration of inflammatory cells in the dermis. Antihistamines and topical steroids were used in most cases for treatment. Conclusion: Vulvar lichen sclerosus et atrophicus causes discomfort and diminishes the quality of life in older women. Early diagnosis and prompt treatment are vital in preventing disease progression and complications. This study will provide valuable data on vulvar lichen sclerosus et atrophicus to dermatologists. (Korean J Dermatol 2020;58(10):643∼649)

손등에 발생한 원발 피부 역형성 대세포 림프종 1예

권창일 ( Chang Il Kwon ),정서미곤 ( Seo Mi Gon Jeong ),김지연 ( Chi Yeon Kim ) 대한피부과학회 2021 대한피부과학회지 Vol.59 No.4

Primary cutaneous anaplastic large cell lymphoma is primary cutaneous lymphoma that is composed of large lymphoid cells with anaplastic and pleomorphic morphology and expresses the CD30 antigen. Generally, primary cutaneous anaplastic large cell lymphoma is represented by a single, erosive plaque located on the trunk or extremities, but rarely on the dorsum of the hand. A 36-year-old man visited our hospital with a plaque on the dorsum of his left hand for 2 months. The plaque was 6×5 cm in size and violet-colored, with erosion. Histopathological findings showed infiltration of large anaplastic cells in the dermis and subcutaneous fat tissue. Immunohistochemically, it showed positive results for CD3, CD4, and CD30 and negativity anaplastic lymphoma kinase. Imaging examination showed no additional lesions, and the diagnosis was confirmed as primary cutaneous anaplastic large cell lymphoma. The patient was treated with radiation therapy four times and the lesion completely disappeared. (Korean J Dermatol 2021;59(4):296∼298)

췌장 및 담도 질환을 위한 생분해성 스텐트/도관

권창일 ( Chang-il Kwon ) 대한췌장담도학회 2020 대한췌담도학회지 Vol.25 No.1

생분해성 스텐트는 인체 장기 내에 삽입 후 제거할 필요가 없다는 매우 매력적인 장점이 있다. 이로 인해 오래 전부터 시장성 및 성공을 염두에 두고 인체 장기별로 여러 가지 생분해성 물질들을 이용한 생분해성 스텐트들이 개발 및 인체 적용이 지속되어 왔다. 소화관 영역에서는 식도 양성 협착을 처음 적응증으로 하여 인체 연구가 시작이 되었으며, 현재는 여러 한계점을 극복하고 양성 담도 협착 및 양성 췌관 협착에도 시도가 되고 있다. 하지만 생분해성 물질이 분해되는 시간을 적절히 조절하면서 확장력을 높게 유지하기 위해서는 원사의 두께를 일정한 두께로 유지할 수밖에 없기 때문에 해결해야 할 문제점들이 적지 않다. 본고에서는 기존 생분해성 스텐트들과 관련된 이슈들 또는 치료 성적들을 인체 장기별로 알아보고자 하였으며, 생분해성 스텐트 개발과 관련된 기초적인 사항들에 대한 개념들 및 해결해야 할 문제점들을 논하였다. Biodegradable stents have the highly attractive advantage that they do not need to be removed after insertion into human organs. For this reason, biodegradable stents using various biodegradable materials have been developed and applied to the several human organs for a long time with the possibility of success. In the gastrointestinal tract, benign esophageal stricture was the first indication of biodegradable stents, and several biodegradable stents are currently attempting to overcome several technical limitations and to be inserted benign bile duct and pancreatic strictures by endoscopic procedure. However, in order to maintain a high radial expansion force while properly controlling the degradation time, there are many problems to be solved because the thickness of the raw material must be adequately maintained at a constant thickness. In this review, the issues or previous clinical results related to biodegradable stents were reviewed, and the concepts of the basics and the problems related to the development of biodegradable stents were discussed.

췌장 및 담도 질환을 위한 일회용 내시경

권창일 ( Chang-il Kwon ) 대한췌장담도학회 2021 대한췌담도학회지 Vol.26 No.1

경피배액술로 치료한 십이지장 벽내 혈종 1예

권창일 ( Chang Il Kwon ),최기현 ( Ki Hyun Choi ),고은향 ( Eun Hyang Ko ),이지현 ( Ji Hyun Lee ),송영준 ( Young Jun Song ),고광현 ( Kwang Hyun Ko ),홍성표 ( Sung Pyo Hong ),박필원 ( Pil Won Park ) 대한소화기학회 2007 대한소화기학회지 Vol.49 No.1

Complicating intramural hematoma is an interesting, relatively unusual condition. Various etiologic factors have been described, with the most common being blunt trauma, anticoagulant therapy, Henoch-Schonlein purpura and blood dyscrasias. Most intramural hematomas resolve spontaneously with conservative treatment, and the prognosis is good. However, if the abdominal pain or obstruction does not resolve with medical management over seven to ten days, complications such as infarction or peritonitis may occur, and surgical intervention might be required. We report a case of intramural hematoma of duodenum treated with percutaneous drainage and embolization of bleeding focus which was complicated with acute pancreatitis after anticoagulation treatment in a patient with recurrent history of deep vein thrombosis. In addition, we reviewed reports of intramural hematoma of the duodenum and treatment strategies. (Korean J Gastroenterol 2007;49:45-49)

항암치료 환자의 B형 및 C형 간염바이러스 감염과 간기능 이상

권창일 ( Chang Il Kwon ),이지현 ( Ji Hyun Lee ),최기현 ( Ki Hyun Choi ),고광현 ( Kwang Hyun Ko ),홍성표 ( Sung Pyo Hong ),황성규 ( Seong Gyu Hwang ),박필원 ( Pil Won Park ),오도연 ( Do Yeun Oh ),임규성 ( Kyu Sung Rim ),김세현 ( Se 대한소화기학회 2006 대한소화기학회지 Vol.48 No.6

목적: 항암화학치료 중 또는 후에 간 기능 이상이 흔히 동반되며, 특히 바이러스에 감염되어 있는 경우 바이러스 재활성화나 증식에 의해 중증 간 기능 이상이나 전격간염이 발생하기도 한다. 그러나 우리나라 바이러스 보유자의 항암 화학치료 후 간 기능 악화에 대한 연구가 미흡하다. 이에 저자들은 단일기관에서 항암화학치료를 받는 악성종양 환자에서 B형 또 C형 간염바이러스 감염의 유병률과 간 기능 이상 발생률, B형 간염바이러스 재활성화율과 만성 B형 간염 환자에서 예방적인 라미부딘 투여 효과 등을 알아보고자 하였다 대상 및 방법 : 2000년 1월부터 2005년 6월까지 포천중문의대 분당차병원에 내원하여 악성종양을 진단받고 항암화학요법을 시행 받은 환자 1,477명을 대상으로 의무기록을 통한 후향 분석을 시행하였다. 바이러스 검사나 간기능 검사가 제대로 시행되지 않았거나 만성 간염에 의해 유발된 간암 환자 등 668명을 제외한 총 809명을 대상으로 분석하였다. 결과: 간염바이러스 유병률은 6.6%였으며, 바이러스 보유자에서 aminotransferase 수치가 유의하게 증가하였다. 그러나 다른 간 기능 수치나 두 군 간에 간 기능 이상 발생률은 유의한 차이가 없었다. B형 간염 환자 40명 중, 항암치료로 인해 바이러스 재활성화가 된 환자는 6명(15%)이었으며, 모두 라미부딘 투여로 HBV DNA 음전과 간기능의 정상화가 유지되었다. 결론: 항암치료를 받는 환자에서 바이러스 보유 상태가 중증의 간기능 이상 발생에 큰 영향을 미치지 않았으며, 이의 원인으로 간 기능 악화에 대한 라미부딘 투여의 예방 및 치료 효과가 영향을 주었을 것이라 추측한다. 향후 바이러스 보유의 영향과 라미부딘 예방 투여의 필요성과 효과에 대해 전향 코호트 연구가 필요하다. Background/Aims: Liver dysfunction and reactivation of hepatitis virus are well-described complications in cancer patients who receive cytotoxic chemotherapy and may result in varying degrees of liver damage. However, there has been just few reports on such complications and on the preemptive use of lamivudine in Korea. The aims of this study were to determine the prevalence of hepatitis B and C virus infection and the incidence of liver dysfunction in patients with malignancies who receive chemotherapy, to determine the reactivation rate of hepatitis B virus (HBV) in those patients, to evaluate the effect of preemptive use of lamivudine in patients with HBV infection. Methods: Among 1,477 patients who received chemotherapy due to various malignancies from January 2000 to June 2005, 668 patients with incomplete viral studies or hepatitis related malignancy were excluded. A retrospective study was conducted by reviewing the medical records of remaining 809 patients. Results: The overall prevalence rate of hepatitis B or C virus in patients receiving chemotherapy was 6.55% (53/809). The incidences of liver dysfunction was not significantly different between hepatitis virus positive group and negative group. Reactivation rate of hepatiris B or C virus after chemotherapy was 15% (6/40). In all patients who received lamivudine therapy, aspartate aminotransferase and alanine aminotransferase level were normalized and HBV DNA negativity achieved. Conclusions: The existence of hepatitis virus in patients receiving chemotherapy did not significantly influence the development of severe liver dysfunction, owing probably to the lamivudine therapy. Further prospective studies are required to ascertain the reactivation of hepatitis virus in patients receiving chemotherapy and the need for prophylactic lamivudine therapy in HBV positive patients. (Korean J Gas­troenterol 2006:48:408-414)